Neurometrix Inc (NURO) 1.73 $NURO
NeuroMetrix, Inc. Announces Date for 2014 Third Quarter Financial Results Conference Call
Business Wire - Tue Oct 21, 6:00AM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue its 2014 third quarter financial results before the opening of the market on October 28, 2014. The Company will host a conference call at 8:00 a.m., Eastern Time on October 28, 2014 to discuss its financial results as well as business developments affecting the Company.
NURO: 1.73 (-0.01)
3 Breakout Stocks Under $10 for Your Watch List
at The Street - Wed Oct 08, 7:25AM CDT
Keep an eye on these under-$10 stocks for breakout trades.
RDNT: 8.70 (+0.12), NURO: 1.73 (-0.01), FSGI: 2.03 (+0.03)
NeuroMetrix Reports Publication of Study Demonstrating that DPNCheck is Effective at Detecting Diabetic Peripheral Neuropathy at all Stages of Severity
Business Wire - Thu Sep 25, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of results from a DPNCheck(R) study conducted at the Diabetes Research Unit of the Ipswich Hospital NHS Trust in the United Kingdom. The study by Sharma and colleagues titled "Assessment of Diabetic Neuropathy Using a Point-of-Care Nerve Conduction Device Shows Significant Associations With the LDIFLARE Method and Clinical Neuropathy Scoring" was published in the Journal of Diabetes Science and Technology and is available at:
NURO: 1.73 (-0.01)
NeuroMetrix CEO to Present at 29th Annual Meeting of Japan Society of Diabetic Complications
Business Wire - Tue Sep 23, 12:49PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D., Ph.D., NeuroMetrix President and Chief Executive Officer, will participate in the 29th Annual Meeting of The Japan Society of Diabetic Complications to be held in Tokyo on October 3 and 4, 2014. The Japan Society of Diabetic Complications is a part of The Japan Diabetes Society which was established in 1958 to promote diabetes-related academic research and treatment programs. The organization has over 16,000 members and works in collaboration with other international organizations including the International Diabetes Federation (IDF), the American Diabetes Association (ADA), and the European Association for the Study of Diabetes (EASD). The Annual Meeting of the Japan Society of Diabetic Complications is one of the major events of the Japan Diabetes Society.
NURO: 1.73 (-0.01)
NeuroMetrix Names Senior Executive to Lead Consumer Healthcare Initiative Frank McGillin - SVP and GM, Consumer
Business Wire - Wed Sep 03, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that it has appointed Frank McGillin as Senior Vice President and General Manager, Consumer. Mr. McGillin will be responsible for development of a consumer healthcare business built on the Company's wearable therapeutic technology for treatment of chronic pain which was recently cleared by the FDA for over-the-counter use without a prescription requirement.
NURO: 1.73 (-0.01)
NeuroMetrix to Present at Rodman & Renshaw Annual Global Investment Conference
Business Wire - Tue Sep 02, 2:51PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference at the New York Palace Hotel, New York, NY on September 8-10, 2014. Dr. Gozani intends to provide an update on the Company's business activities including the SENSUS(R) Pain Management System for chronic pain and sleep, and the Company's emerging consumer healthcare initiative.
NURO: 1.73 (-0.01)
Bacterin Announces the Appointment of New Board Member
GlobeNewswire - Wed Aug 13, 6:30AM CDT
Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of David Goodman, MD, MSE to the board of directors. Dr. Goodman brings extensive experience in executive management through previous roles as CEO of SEDLine and EVP of Business Development for Masimo (Nasdaq:MASI). The Board unanimously elected Dr. Goodman to fill the vacancy created by Mitchell Godfrey's recent resignation. Bacterin would like to thank Mr. Godfrey for his years of service and dedication to the Company.
MASI: 22.05 (+0.21), BONE: 4.63 (+0.35), NURO: 1.73 (-0.01)
NeuroMetrix Reports Second Quarter 2014 Financial Results and Business Highlights
Business Wire - Thu Jul 24, 6:00AM CDT
--FDA regulatory clearance for over-the-counter wearable technology to treat chronic pain
NURO: 1.73 (-0.01)
NeuroMetrix Marks 10th Year Anniversary of Listing on NASDAQ
Business Wire - Tue Jul 22, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ: NURO) reported today that it had reached the 10th anniversary of its initial listing on NASDAQ.
NURO: 1.73 (-0.01)
NeuroMetrix, Inc. Announces Date for 2014 Second Quarter Financial Results Conference Call
Business Wire - Thu Jul 17, 2:32PM CDT
NeuroMetrix, Inc. (the "Company" (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue its 2014 second quarter financial results before the opening of the market on July 24, 2014. The Company will host a conference call at 8:00 a.m., Eastern Daylight Time on July 24, 2014 to discuss its financial results as well as business developments affecting the Company.
NURO: 1.73 (-0.01)
Healthcare Companies Announce Upcoming Earnings Schedules, and Receive FDA Approvals and Clearances - Analyst Notes on WellPoint, Anacor, NeuroMetrix, Ophthotech and Emergent BioSolutions
PR Newswire - Fri Jul 11, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), NeuroMetrix Inc. (NASDAQ: NURO), Ophthotech Corporation (NASDAQ: OPHT) and Emergent BioSolutions, Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4686-100free.
EBS: 21.14 (-0.07), NURO: 1.73 (-0.01), OPHT: 39.47 (-0.41), ANAC: 27.46 (-0.78), WLP: 119.42 (-1.01)
NeuroMetrix's OTC Pain Management Device Gets FDA Nod, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 1:50PM CDT
Following the news, NeuroMetrix's (NURO) share price surged 19% to eventually close at $2.25 yesterday.
CSII: 27.34 (-0.45), NURO: 1.73 (-0.01), HSP: 50.97 (+0.09), OSUR: 8.30 (-0.16)
Why NeuroMetrix (NURO) Stock Is Soaring Today
at The Street - Tue Jul 08, 9:21AM CDT
NeuroMetrix (NURO) soared Tuesday after the FDA cleared the medical device company's wearable technology for over-the-counter use in treating chronic pain.
NURO: 1.73 (-0.01)
FDA Clears NeuroMetrix Wearable Technology for Over-the-Counter Use in Treatment of Chronic Pain
Business Wire - Tue Jul 08, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its wearable technology for treatment of chronic pain received 510(k) clearance (K140333) from the U.S. Food and Drug Administration (FDA) for over-the-counter use.
NURO: 1.73 (-0.01)
NICE Guidelines to Boost Boston Scientific's Rhythm Management - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 2:00PM CDT
The new guidance released by NICE on use of cardiac technologies for arrhythmias and heart failure is expected to boost Boston Scientific Corporation's (BSX) Rhythm Management business in Europe.
BSX: 12.45 (+0.42), ICUI: 70.58 (+0.39), NURO: 1.73 (-0.01), CRDC: 0.99 (-0.01)
Haemonetics Suffers on Dismal Q4, Poor FY15 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 1:55PM CDT
On Jun 27, 2014, we issued an updated research report on Haemonetics Corporation (HAE).
ICUI: 70.58 (+0.39), NURO: 1.73 (-0.01), HAE: 34.97 (+0.57), CRDC: 0.99 (-0.01)
Omeros Corporation (OMER) Gains: Stock Up 8.92% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:44AM CDT
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise 9% on the day.
ICUI: 70.58 (+0.39), NURO: 1.73 (-0.01), CRDC: 0.99 (-0.01), OMER: 11.91 (-0.21)
Quality Systems Teams Up With 3M Health Information Systems - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 12:50PM CDT
Quality Systems (QSII) continues to report a fall in earnings and revenues but we are still optimistic about the company given the continued strength in its NextGen subsidiary as well as the expected benefit from its Mirth acquisition.
NURO: 1.73 (-0.01), CRDC: 0.99 (-0.01), QSII: 14.02 (+0.11)
Cerner Enters New Agreement with North Carolina's Mission Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 12:40PM CDT
Under the new agreement, signed on Mar 28, Cerner Corporation (CERN) will help Mission Health control IT costs, align strategies, and improve the quality of care.
NURO: 1.73 (-0.01), CRDC: 0.99 (-0.01), CERN: 58.57 (-0.61)
LeMaitre Vascular (LMAT) Soars: Stock Adds 10.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 7:51AM CDT
LeMaitre Vascular, Inc. (LMAT) was a big mover last session, as its shares rose nearly 11% on the day.
ICUI: 70.58 (+0.39), NURO: 1.73 (-0.01), LMAT: 6.92 (+0.02), CRDC: 0.99 (-0.01)
NeuroMetrix, Inc. Announces Date for 2014 Third Quarter Financial Results Conference Call
Business Wire - Tue Oct 21, 6:00AM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue its 2014 third quarter financial results before the opening of the market on October 28, 2014. The Company will host a conference call at 8:00 a.m., Eastern Time on October 28, 2014 to discuss its financial results as well as business developments affecting the Company. NURO: 1.73 (-0.01)
3 Breakout Stocks Under $10 for Your Watch List
at The Street - Wed Oct 08, 7:25AM CDT
Keep an eye on these under-$10 stocks for breakout trades.
RDNT: 8.70 (+0.12), NURO: 1.73 (-0.01), FSGI: 2.03 (+0.03)
NeuroMetrix Reports Publication of Study Demonstrating that DPNCheck is Effective at Detecting Diabetic Peripheral Neuropathy at all Stages of Severity
Business Wire - Thu Sep 25, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of results from a DPNCheck(R) study conducted at the Diabetes Research Unit of the Ipswich Hospital NHS Trust in the United Kingdom. The study by Sharma and colleagues titled "Assessment of Diabetic Neuropathy Using a Point-of-Care Nerve Conduction Device Shows Significant Associations With the LDIFLARE Method and Clinical Neuropathy Scoring" was published in the Journal of Diabetes Science and Technology and is available at:
NURO: 1.73 (-0.01)
NeuroMetrix CEO to Present at 29th Annual Meeting of Japan Society of Diabetic Complications
Business Wire - Tue Sep 23, 12:49PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D., Ph.D., NeuroMetrix President and Chief Executive Officer, will participate in the 29th Annual Meeting of The Japan Society of Diabetic Complications to be held in Tokyo on October 3 and 4, 2014. The Japan Society of Diabetic Complications is a part of The Japan Diabetes Society which was established in 1958 to promote diabetes-related academic research and treatment programs. The organization has over 16,000 members and works in collaboration with other international organizations including the International Diabetes Federation (IDF), the American Diabetes Association (ADA), and the European Association for the Study of Diabetes (EASD). The Annual Meeting of the Japan Society of Diabetic Complications is one of the major events of the Japan Diabetes Society.
NURO: 1.73 (-0.01)
NeuroMetrix Names Senior Executive to Lead Consumer Healthcare Initiative Frank McGillin - SVP and GM, Consumer
Business Wire - Wed Sep 03, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that it has appointed Frank McGillin as Senior Vice President and General Manager, Consumer. Mr. McGillin will be responsible for development of a consumer healthcare business built on the Company's wearable therapeutic technology for treatment of chronic pain which was recently cleared by the FDA for over-the-counter use without a prescription requirement.
NURO: 1.73 (-0.01)
NeuroMetrix to Present at Rodman & Renshaw Annual Global Investment Conference
Business Wire - Tue Sep 02, 2:51PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference at the New York Palace Hotel, New York, NY on September 8-10, 2014. Dr. Gozani intends to provide an update on the Company's business activities including the SENSUS(R) Pain Management System for chronic pain and sleep, and the Company's emerging consumer healthcare initiative.
NURO: 1.73 (-0.01)
Bacterin Announces the Appointment of New Board Member
GlobeNewswire - Wed Aug 13, 6:30AM CDT
Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of David Goodman, MD, MSE to the board of directors. Dr. Goodman brings extensive experience in executive management through previous roles as CEO of SEDLine and EVP of Business Development for Masimo (Nasdaq:MASI). The Board unanimously elected Dr. Goodman to fill the vacancy created by Mitchell Godfrey's recent resignation. Bacterin would like to thank Mr. Godfrey for his years of service and dedication to the Company.
MASI: 22.05 (+0.21), BONE: 4.63 (+0.35), NURO: 1.73 (-0.01)
NeuroMetrix Reports Second Quarter 2014 Financial Results and Business Highlights
Business Wire - Thu Jul 24, 6:00AM CDT
--FDA regulatory clearance for over-the-counter wearable technology to treat chronic pain
NURO: 1.73 (-0.01)
NeuroMetrix Marks 10th Year Anniversary of Listing on NASDAQ
Business Wire - Tue Jul 22, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ: NURO) reported today that it had reached the 10th anniversary of its initial listing on NASDAQ.
NURO: 1.73 (-0.01)
NeuroMetrix, Inc. Announces Date for 2014 Second Quarter Financial Results Conference Call
Business Wire - Thu Jul 17, 2:32PM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue its 2014 second quarter financial results before the opening of the market on July 24, 2014. The Company will host a conference call at 8:00 a.m., Eastern Daylight Time on July 24, 2014 to discuss its financial results as well as business developments affecting the Company. NURO: 1.73 (-0.01)
Healthcare Companies Announce Upcoming Earnings Schedules, and Receive FDA Approvals and Clearances - Analyst Notes on WellPoint, Anacor, NeuroMetrix, Ophthotech and Emergent BioSolutions
PR Newswire - Fri Jul 11, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), NeuroMetrix Inc. (NASDAQ: NURO), Ophthotech Corporation (NASDAQ: OPHT) and Emergent BioSolutions, Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4686-100free.
EBS: 21.14 (-0.07), NURO: 1.73 (-0.01), OPHT: 39.47 (-0.41), ANAC: 27.46 (-0.78), WLP: 119.42 (-1.01)
NeuroMetrix's OTC Pain Management Device Gets FDA Nod, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 1:50PM CDT
Following the news, NeuroMetrix's (NURO) share price surged 19% to eventually close at $2.25 yesterday.
CSII: 27.34 (-0.45), NURO: 1.73 (-0.01), HSP: 50.97 (+0.09), OSUR: 8.30 (-0.16)
Why NeuroMetrix (NURO) Stock Is Soaring Today
at The Street - Tue Jul 08, 9:21AM CDT
NeuroMetrix (NURO) soared Tuesday after the FDA cleared the medical device company's wearable technology for over-the-counter use in treating chronic pain.
NURO: 1.73 (-0.01)
FDA Clears NeuroMetrix Wearable Technology for Over-the-Counter Use in Treatment of Chronic Pain
Business Wire - Tue Jul 08, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its wearable technology for treatment of chronic pain received 510(k) clearance (K140333) from the U.S. Food and Drug Administration (FDA) for over-the-counter use.
NURO: 1.73 (-0.01)
NICE Guidelines to Boost Boston Scientific's Rhythm Management - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 2:00PM CDT
The new guidance released by NICE on use of cardiac technologies for arrhythmias and heart failure is expected to boost Boston Scientific Corporation's (BSX) Rhythm Management business in Europe.
BSX: 12.45 (+0.42), ICUI: 70.58 (+0.39), NURO: 1.73 (-0.01), CRDC: 0.99 (-0.01)
Haemonetics Suffers on Dismal Q4, Poor FY15 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 1:55PM CDT
On Jun 27, 2014, we issued an updated research report on Haemonetics Corporation (HAE).
ICUI: 70.58 (+0.39), NURO: 1.73 (-0.01), HAE: 34.97 (+0.57), CRDC: 0.99 (-0.01)
Omeros Corporation (OMER) Gains: Stock Up 8.92% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:44AM CDT
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise 9% on the day.
ICUI: 70.58 (+0.39), NURO: 1.73 (-0.01), CRDC: 0.99 (-0.01), OMER: 11.91 (-0.21)
Quality Systems Teams Up With 3M Health Information Systems - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 12:50PM CDT
Quality Systems (QSII) continues to report a fall in earnings and revenues but we are still optimistic about the company given the continued strength in its NextGen subsidiary as well as the expected benefit from its Mirth acquisition.
NURO: 1.73 (-0.01), CRDC: 0.99 (-0.01), QSII: 14.02 (+0.11)
Cerner Enters New Agreement with North Carolina's Mission Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 12:40PM CDT
Under the new agreement, signed on Mar 28, Cerner Corporation (CERN) will help Mission Health control IT costs, align strategies, and improve the quality of care.
NURO: 1.73 (-0.01), CRDC: 0.99 (-0.01), CERN: 58.57 (-0.61)
LeMaitre Vascular (LMAT) Soars: Stock Adds 10.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 7:51AM CDT
LeMaitre Vascular, Inc. (LMAT) was a big mover last session, as its shares rose nearly 11% on the day.
ICUI: 70.58 (+0.39), NURO: 1.73 (-0.01), LMAT: 6.92 (+0.02), CRDC: 0.99 (-0.01)
